Are you at least 21 years old?
You must be at least 21 to see this content, you will be redirected to google
Are you at least 21 years old?
You must be at least 21 to see this content, you will be redirected to google
A
• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)
• attention-deficit-hyperactivity-disorder-adhd (5)
B
C
D
• d9-tetrahydrocannabinol-thc (4)
• d9-tetrahydrocannabinolic-acid-thca (1)
E
• endocannabinoid-system-ecs (45)
F
G
• gastrointestinal-disease (6)
H
I
K
L
M
N
• national-institute-on-drug-abuse-nida (1)
• neuro-protective-and-neuro-generative (7)
P
S
T
• traumatic-brain-injury-tbi (1)
• View All (505)Cannabinoid Receptor Agonist-induced Apoptosis of Human Prostate Cancer Cells LNCaP Proceeds through Sustained Activation of ERK12 Leading to G1 Cell Cycle Arrest (2006)
These data suggest that cannabinoid receptor agonists should be considered as novel agents for the treatment of prostate cancer, considering that the expression levels of both CB1 and CB2 cannabinoid receptors are higher in human prostate cancer cells than in epithelial cells. of normal prostate, View study
Cannabinoid receptor as a novel target for the treatment of prostate cancer (2015)
The cannabinoids, the active components of Cannabis sativa, have received great interest due to their multiple pharmacological properties, such as the inhibition of cell growth, the anti-inflammatory effects and the regression of tumors. Our results suggest that various non-habit forming cannabinoid receptor agonists could be developed as new therapeutic agents for the treatment of prostate cancer. View study